X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (80) 80
Book Review (16) 16
Book Chapter (2) 2
Publication (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
eribulin (63) 63
index medicus (56) 56
oncology (50) 50
chemotherapy (42) 42
breast cancer (41) 41
metastasis (36) 36
cancer (33) 33
humans (33) 33
metastatic breast cancer (29) 29
eribulin mesylate (28) 28
mesylate (24) 24
female (21) 21
anthracycline (19) 19
care and treatment (19) 19
research (19) 19
analysis (16) 16
drug therapy (16) 16
patients (16) 16
tumors (15) 15
cancer therapies (14) 14
furans - administration & dosage (14) 14
furans - pharmacology (14) 14
halichondrin b analog (14) 14
ketones - administration & dosage (14) 14
ketones - pharmacology (14) 14
taxane (14) 14
e7389 (13) 13
furans - adverse effects (13) 13
furans - therapeutic use (13) 13
ketones - adverse effects (13) 13
ketones - therapeutic use (13) 13
medicine & public health (13) 13
phase-ii (13) 13
sarcoma (13) 13
breast neoplasms - drug therapy (12) 12
capecitabine (12) 12
epithelial-mesenchymal transition (12) 12
middle aged (12) 12
patient outcomes (12) 12
treatment outcome (12) 12
adult (11) 11
aged (11) 11
health aspects (11) 11
survival (11) 11
therapy (11) 11
breast neoplasms - pathology (10) 10
clinical trials (10) 10
halichondrin-b (10) 10
mesylate e7389 (10) 10
metastases (10) 10
neutropenia (10) 10
oncology, experimental (10) 10
open-label (10) 10
animals (9) 9
anthracyclines (9) 9
antineoplastic agents - adverse effects (9) 9
metastatic breast-cancer (9) 9
neoplasm metastasis (9) 9
safety (9) 9
women (9) 9
cancer patients (8) 8
dosage and administration (8) 8
eribulin mesilate (8) 8
antineoplastic agents - administration & dosage (7) 7
antineoplastic agents - pharmacology (7) 7
antineoplastic agents - therapeutic use (7) 7
cell line, tumor (7) 7
development and progression (7) 7
disease-free survival (7) 7
gene expression (7) 7
medical prognosis (7) 7
original (7) 7
pharmacokinetics (7) 7
physicians choice (7) 7
advanced solid tumors (6) 6
apoptosis (6) 6
cancer research (6) 6
cell biology (6) 6
doxorubicin (6) 6
drug dosages (6) 6
emt (6) 6
locally recurrent (6) 6
monotherapy (6) 6
neoplasms. tumors. oncology. including cancer and carcinogens (6) 6
original article (6) 6
paclitaxel (6) 6
pharmacology (6) 6
review (6) 6
sarcoma - pathology (6) 6
usage (6) 6
womens health (6) 6
xenograft model antitumor assays (6) 6
breast (5) 5
diagnosis (5) 5
drug administration schedule (5) 5
efficacy (5) 5
growth (5) 5
halichondrin-b analog (5) 5
liposarcoma (5) 5
mice (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
European Journal of Cancer, ISSN 0959-8049, 05/2019, Volume 112, pp. 57 - 65
The objective of this study was to evaluate the efficacy and safety of eribulin monotherapy, relative to vinorelbine, in Chinese women with locally... 
Eribulin | Tolerability | Progression-free survival | Locally recurrent or metastatic breast cancer | MESYLATE | CAPECITABINE | SURVIVAL | MONOTHERAPY | ONCOLOGY | ANTHRACYCLINE | CHEMOTHERAPY | Relapse | Chemotherapy | Clinical trials | Breast cancer | Metastasis | Diseases | Cancer | Taxane | Survival | Metastases | Confidence intervals | Randomization | Anthracycline | Response rates | Safety | Vinorelbine
Journal Article
CANCER SCIENCE, ISSN 1349-7006, 01/2018, Volume 109, pp. 380 - 380
Conference Proceeding
Breast Cancer, ISSN 1340-6868, 05/2018, Volume 25, Issue 3, pp. 370 - 374
This post hoc subgroup analysis of a large phase 3 study compared the efficacy and safety of eribulin versus capecitabine in patients with human epidermal... 
Subgroup analysis | Metastatic breast cancer | Eribulin | Overall survival | Capecitabine | MONOTHERAPY | DOCETAXEL | CHEMOTHERAPY | OBSTETRICS & GYNECOLOGY | MESYLATE | TRIAL | WOMEN | THERAPY | ONCOLOGY | ANTHRACYCLINE | PRETREATED PATIENTS | Chemotherapy | Epidermal growth factor | Analysis | Breast cancer | Metastasis | Cancer | Index Medicus | Rapid Communication
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 8/2017, Volume 80, Issue 2, pp. 377 - 384
Journal Article
YAKUGAKU ZASSHI, ISSN 0031-6903, 2016, Volume 136, Issue 7, pp. 1023 - 1029
It is often necessary to modify the dose or schedule of eribulin mesilate (Eri) because of adverse events. Therefore, we retrospectively investigated the... 
dose adjustment | relative dose intensity | eribulin mesilate | metastatic breast cancer
Journal Article
YAKUGAKU ZASSHI, ISSN 0031-6903, 2016
It is often necessary to modify the dose or schedule of Eri (eribulin mesilate) because of adverse events. Therefore, we retrospectively investigated the... 
dose adjustment | Relative Dose Intensity | Eribulin Mesilate | metastatic breast cancer
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9769, pp. 914 - 923
Journal Article
Japanese Journal of Clinical Oncology, ISSN 0368-2811, 02/2017, Volume 47, Issue 2, pp. 137 - 144
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 12/2014, Volume 148, Issue 3, pp. 553 - 561
Journal Article
British Journal of Cancer, ISSN 0007-0920, 05/2016, Volume 114, Issue 11, pp. 1212 - 1218
Journal Article